On August 24, Erasca (NASDAQ:ERAS) announced that the FDA had granted Fast Track Designation to ERAS-0015, its oral pan-RAS molecular glue, for patients with metastatic pancreatic adenocarcinoma. The designation gives Erasca more frequent contact with regulators and, if the drug keeps clearing bars, a shot at accelerated approval, priority review, and rolling review. For a company still years from a commercial product, that kind of regulatory shortcut matters as much as the science behind it.
A Molecule Turning Heads
ERAS-0015 is designed to inhibit RAS signaling across multiple mutation types, and the data behind the Fast Track news is what makes the designation notable rather than routine. In July, Erasca reported updated results from its AURORAS-1 Phase 1 trial showing a 57% response rate in patients with second-line or later KRAS G12X pancreatic cancer who received ERAS-0015 monotherapy at the 32 mg recommended dose.
Every patient who responded was still on treatment as of the May 25 data cutoff, and the company said tolerability held up with longer follow-up, including a median relative dose intensity of 100%. Erasca is also combining ERAS-0015 with panitumumab, and it cleared the first 16 mg dose escalation cohort without any dose-limiting toxicities while pushing into a 24 mg cohort. CEO Jonathan Lim said the company plans to work with the FDA on a Phase 3 pancreatic cancer trial alongside two more pivotal studies in lung cancer, with a registration-enabling lung cancer trial targeted for the first half of 2027 and pancreatic and lung Phase 3 studies expected to begin between 2027 and early 2028.
The Cost Of Moving Fast
Running three potentially registration-enabling trials at once is expensive, and Erasca’s second-quarter 2026 results show that the bill is starting to show up. R&D expenses rose to $35.9 million for the quarter, up from $21.2 million a year earlier, while general and administrative costs climbed to $11.7 million from $9.5 million. Net loss widened to $44.1 million, or $0.14 per share, compared to $33.9 million, or $0.12 per share, in the same quarter last year.
Erasca has funded the gap by going back to the public markets twice in 2026, raising about $258.8 million in January and another $632.5 million in an upsized offering in July, leaving it with $384.3 million in cash as of June 30. That cash should cover the milestones ahead, but repeated offerings mean existing shareholders keep absorbing dilution while the pipeline is still in Phase 1.
Funds Are Leaning In
Hedge fund ownership rose to 56 funds holding Erasca from 51 the prior quarter, a modest but real uptick in institutional interest around the time of the pancreatic cancer data. Short interest sits at 9.76% of the float, a level that reflects a real bear camp rather than passing skepticism, and it leaves room for a sharp move if the registration-enabling trials keep delivering. The market is essentially pricing the story on clinical outcomes rather than financial fundamentals.
Where This Goes Next
Erasca has cleared a regulatory hurdle and produced early response data that gave it enough conviction to fund three pivotal trials, but pivotal trials also mean years before ERAS-0015 could reach patients commercially, if it gets there at all. For the encouraging signs to hold, the monotherapy and combination data due in the first half of 2027 need to confirm what the smaller 2026 cohorts suggested.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Follow Insider Monkey on Google News.
Hedge Fund Resource Center